Grail (GRAL) Q3 2026 earnings review
FDA panel backs Grail's cancer test, but price cuts hurt sales
Grail cleared its biggest regulatory test while its commercial numbers stepped back on heavier discounting and marketing costs. An FDA advisory panel voted in favor of approving the Galleri cancer blood test, and chief executive Josh Ofman expects a final decision by early in the first quarter of 2027. However, screening sales fell 13% from the second quarter to $37 million as promotional pricing cut revenue per test to about $666 by our math, pushing gross margin excluding one-offs down to 42%.
| Galleri screening revenue | $37.3M +14% from a year ago, −13% from Q2 |
|---|---|
| Galleri test volume | >56,000 +24% from a year ago, −8% from Q2 |
| Gross margin, excluding one-offs | 42% 55% a year ago |
| FDA approval decision outlook | Early Q1 2027 follow-up to September panel backing |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because regulatory progress balanced out weaker unit economics. Winning the advisory committee vote and publishing trial data in top medical journals reduced the risk of an FDA rejection. The bad news: sales and marketing costs jumped 63% from a year ago even as test volume slipped from the second quarter, and gross margin fell ahead of a 7% sales royalty to Illumina that starts in late December.
The question now is whether third-quarter sales slowed only on summer doctor vacations and introductory discounts, or because self-pay demand is tiring before insurance coverage arrives. If the enlarged sales force and new journal papers work, fourth-quarter test volume and prices will rebound; if self-pay demand is thinning, discounts and marketing losses will keep widening. Fourth-quarter volume and the early 2027 FDA decision will settle it.
🐂 Bull Case
FDA Panel Backing Clears the Main Hurdle
Grail sells Galleri, a blood test that screens for more than 50 types of cancer before symptoms appear. Full approval from the Food and Drug Administration (FDA) is the central goal for the healthcare group, because broad insurance and future government coverage depend on it. Chief executive Josh Ofman said that "GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee".
The panel met in September, at the very start of the company's autumn target window, and voted in favor of the test. Following that vote, the California company narrowed its expected timeline and now "anticipates an FDA decision by early Q1 2027" rather than its earlier view of the first part of the year. This removes the risk of a negative panel vote that could have stalled the application.
What to watch: the final FDA approval decision and the approved patient label by early in the first quarter of 2027. An approval covering adults aged 50 and older would allow Grail to pursue commercial insurance contracts and qualify for the future Medicare coverage pathway.
Medical Journals Published Major Trial Results
Doctors and health plans have waited for peer-reviewed publications from Grail's two largest clinical studies before recommending the blood test widely. This quarter, The New England Journal of Medicine and Nature Medicine published results from the UK National Health Service trial and the North American PATHFINDER 2 study, covering about 175,000 people. The UK trial had previously missed its primary goal of cutting combined Stage III and IV cancers.
The published papers highlight a "reduction of >20% in Stage IV diagnoses of 12 prespecified aggressive cancers" and a 25% drop in cancers found during emergency room visits. Across both studies, adding Galleri to standard screening multiplied cancer detection by 4 to 6.5 times. Having these findings in top medical journals gives the expanded sales force published evidence to show primary care doctors.
What to watch: fourth-quarter test volume following these publications. A rebound above the second quarter's 61,000 tests would show that peer-reviewed data is convincing more doctors to order the test.
Positives this quarter didn't test
Two commercial growth drivers from earlier quarters received no new figures in the third-quarter earnings release.
- International expansion: screening sales outside the US rose to $1.2 million in the second quarter alongside a partnership with Samsung for Asian markets; the third-quarter filing's geographic table will show the next reading.
- Electronic health record ordering: Grail plans broad availability inside the Epic hospital software system by the end of 2026; fourth-quarter commentary will show whether the rollout finished on time.
🐻 Bear Case
Discounts Cut Screening Revenue despite Easy Comparison
"We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction," Ofman said. Management also expanded its US sales territories by a third in the first half of the year, and rival multi-cancer tests have entered the market. Yet third-quarter numbers moved the other way, even against a weak third quarter last year when volume stood flat.
- Galleri test volume: more than 56,000 tests, up 24% from a year ago but down 8.2% from 61,000 in the second quarter by our math
- Screening revenue: $37.3 million, up 13.6% from a year ago and down 12.6% from $42.6 million last quarter
- Revenue per test: about $666 by our math, down 8.7% from about $729 a year ago and down from about $699 in the second quarter
Summer vacations normally slow third-quarter doctor visits, but screening revenue fell more than three times as fast from the second quarter as it did last year. Promotional pricing and lower-priced employer and digital-health channels are taking a larger bite out of each sale, keeping revenue growth 10 percentage points behind volume growth.
What to watch: fourth-quarter screening revenue against the 22% to 32% full-year growth target set at the start of the year, which the release did not mention. By our math, Grail needs 16.7% growth in the fourth quarter just to reach the bottom of that range.
Higher Test Costs Reduced Gross Margin
Grail tracks gross margin excluding one-offs — which strips out $33.5 million of quarterly intangible asset write-downs and stock pay — to measure the direct profit on its blood tests. Management has previously pointed to a long-term gross margin target of 50% to 60%. In the third quarter, gross profit excluding one-offs fell 20.5% from a year ago to $15.9 million, and the margin dropped 12.9 percentage points to 42.4%.
The cost of running screening tests rose from 44.0% of total revenue a year ago to 58.7% this quarter, an increase of 14.7 percentage points. Lower selling prices per test and a 92.1% drop in high-margin development services revenue drove the squeeze. This leaves a much weaker starting point before December 24, 2026, when Grail must resume paying former parent Illumina a 7% royalty on oncology sales.
What to watch: first-quarter 2027 gross margin excluding one-offs, the first full quarter carrying the 7% Illumina royalty. A reading near 35% would confirm that price discounts and royalties have pushed the 50% to 60% target out of reach without insurance reimbursement.
Marketing Spend Rose as Share Count Climbed
Even if the FDA approves Galleri in early 2027, the new federal law covering multi-cancer screening does not open Medicare payment until January 1, 2029 at the earliest. Grail must fund its operations across that multi-year gap, and its operating loss widened from $125.3 million a year ago to $144.6 million this quarter. Loss before interest, taxes, depreciation and write-downs, excluding one-offs, grew 29.1% to $92.6 million.
Sales and marketing was the expense line that moved, rising 63.5% from a year ago to $41.7 million, or 111.1% of total revenue (up 40.6 percentage points). The testing company spent more on marketing than it brought in from all sales. Meanwhile, past stock sales raised the weighted-average share count by 29.5% from a year ago to 46.8 million shares, diluting existing holders to fund the spending.
What to watch: full-year 2026 cash burn against the company's earlier target of under $300 million. If quarterly marketing spend stays above $40 million, Grail will need to issue more shares well before Medicare coverage begins in 2029.
Risks this quarter didn't answer
Four standing concerns from prior quarters cannot be read from the third-quarter earnings release alone.
- New ordering doctors: additions slowed from 1,300 in the first quarter to 1,000 in the second despite 30 new sales territories; the quarterly filing or conference call will show whether additions held up.
- Repeat testing rate: last reported at 30% of volume at the end of 2025 and missing in 2026; any update on the call will show how many patients return for annual screening.
- UK National Health Service rollout: a joint committee is deciding whether to deploy Galleri in the UK after the trial missed its primary endpoint; the filing will show if a timeline exists.
- Shareholder lawsuits: class-action and board lawsuits over the UK trial disclosures were filed in June; the quarterly filing's legal footnote will carry any status change.
💲 Other KPIs
Cash, cash equivalents and short-term marketable securities fell by $72.9 million from $861.6 million at the end of the second quarter, by our math (excluding $6.9 million of restricted cash). The balance is down $115.8 million since the start of the year even after collecting $109 million net from the Samsung share sale in the second quarter.
Revenue from research and development work for pharmaceutical partners fell 92.1% from $3.39 million a year ago and dropped 87.0% from $2.05 million in the second quarter. Because this line shrank by $3.1 million from a year ago, Grail's total revenue grew only 3.7% despite 13.6% growth in Galleri screening revenue.
Spending on research and clinical studies fell 9.4% from $48.6 million a year ago and dropped 7.1% from $47.4 million in the second quarter. As a share of revenue, research spending declined by 17.0 percentage points from a year ago to 117.4%, reflecting the wrap-up of the large UK and PATHFINDER 2 clinical trials.
🔮 Guidance
Unchanged. Grail now expects an FDA approval decision on the Galleri blood test by early in the first quarter of 2027, tightening its earlier phrasing of the first part of 2027 after September's favorable advisory panel vote. The release gave no financial outlook and again left the prior 22% to 32% full-year Galleri revenue growth target unmentioned.
❓ Key Questions
Is the 22%–32% full-year Galleri growth outlook still active?
Management said in the first quarter it would revisit the 22% to 32% target after mid-year, but skipped it in both the second and third quarters. Nine-month Galleri revenue is up 24.3%, requiring 16.7% fourth-quarter growth to hit the low end.
How many new doctors ordered Galleri in the third quarter?
Grail finished expanding its sales territories from about 90 to 120 in June, yet new ordering doctors slowed to 1,000 in the second quarter. The third-quarter count will show if the larger sales team is adding doctors or hitting a ceiling.
How much did promotional pricing cut the average test price?
By our math, revenue per test fell to about $666 from $699 in the second quarter and $729 a year ago. Investors need to know how much of that drop came from temporary promotions versus permanent employer and digital-health discounts.
How will Grail absorb the 7% Illumina royalty in 2027?
Gross margin excluding one-offs fell to 42.4% this quarter before the 7% royalty on oncology sales resumes on December 24, 2026. Management has not explained how it can bridge from roughly 35% after royalties to its 50%–60% long-term target.